PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 2193380
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 2193380
The North America Flexible Endoscopic Surgery Robot Market reached USD 657.3 million in 2025 and is projected to grow at an 11.7% CAGR from 2026 to 2035. The market is expected to cross USD 1.98 billion valuation by 2035. Robotic platforms, procedure accessories, navigation software, and service contracts support minimally invasive flexible procedures. Established bronchoscopy programs increasingly generate demand through utilization rather than new system placements alone. Urological use and potential gastrointestinal commercialization broaden the clinical setting, while authorization, reimbursement, and training influence adoption.
| Market Scope | |
|---|---|
| Start Year | 2025 |
| Forecast Year | 2026-2035 |
| Start Value | $657.3 Million |
| Forecast Value | $1.98 Billion |
| CAGR | 11.7% |
Broader lung cancer screening eligibility expands the flow of nodules requiring tissue diagnosis. Robotic bronchoscopy serves this diagnostic pathway, supporting recurring accessory and service demand beyond capital-equipment cycles. Outpatient surgical infrastructure creates additional venues where procedural volume, specialist staffing, and reimbursement can support a robotic program. These conditions matter more than facility availability alone. Navigation improvements address another adoption barrier by helping clinicians manage anatomical change and verify targets. AI and integrated imaging can reduce manual steps and make workflows more accessible to community hospitals. Commercial demand therefore combines established respiratory utilization with selective outpatient deployment, where confidence, staffing efficiency, and a viable operating model influence whether hospitals and centers adopt or expand a platform.
Based on category, therapeutic generated USD 425.9 million in 2025. Lesion treatment, stone management, resections, and other interventions broaden the role of flexible robotic equipment beyond navigation and diagnosis. Controlled access and precise instrument use influence its relevance to these procedures. Customers assess whether the platform can support more demanding clinical workflows within their existing care setting. Commercial opportunity depends on suitable indications and the resources required to perform them. The segment reflects a shift toward using robotic assistance within treatment pathways, with procedural capability and clinical integration determining how established platforms can serve additional interventions and contribute to the economics of an installed program.
By application, urology generated USD 217.4 million in 2025. Minimally invasive stone management and other upper-tract procedures provide established pathways for robotic assistance. This clinical base gives providers a route to extend utilization beyond pulmonary programs. Outpatient delivery can support adoption where scheduling and physician expertise align with the required procedure volumes. Commercial demand consequently depends on clinical organization alongside equipment availability. Providers need appropriate staff and a viable workflow to use the platform consistently. The application offers a comparatively established setting for additional robotic activity, linking surgical capability with the practical conditions that determine recurring instrument purchasing and use within hospital or ambulatory programs.
The United States flexible endoscopic surgery robot market is projected to generate USD 1.85 billion by 2035. Early regulatory access, reimbursement pathways, hospital infrastructure, and outpatient facilities support adoption. These conditions connect authorization with training and clinical utilization. Academic centers also provide potential commercial sites for newly cleared gastrointestinal systems. Demand increasingly depends on productivity within the installed base, making navigation improvements and broader indications commercially relevant. Hospital and ambulatory purchasing pathways influence expansion decisions. Suppliers need to support procedural performance and account development, converting early placement into recurring use through instruments and service while addressing the clinical and operational requirements of different facility settings.
Intuitive Surgical held over 58% market share in 2025. Ion's installed base and shape-sensing navigation support its position in robotic bronchoscopy. Accessories and service provide continuing demand as facilities use their platforms. Familiarity among clinicians and institutional customers also influences renewal and expansion decisions. AI and imaging enhancements address expectations for procedural confidence and workflow efficiency. The company's commercial position therefore connects installed relationships with continued platform development. Hospitals assess whether their equipment can keep pace with imaging requirements and clinical workflows. These resources help Intuitive support existing accounts while maintaining the relevance of Ion within programs that increasingly evaluate utilization and recurring procedure support alongside initial capital investment.
Some of the major players in this market are JandJ / Auris Health, Noah Medical, Boston Scientific, Olympus Corporation of the Americas, EndoRobotics, and Medivators (Cantel Medical / Steris). Monarch and Galaxy compete in established bronchoscopy workflows. Boston Scientific brings gastrointestinal tools and physician relationships, while Olympus's distribution arrangement supports ROBOPERA access. Medivators contributes indirectly through reprocessing, maintenance, and infection-control services. Clinical evidence, navigation, training, and operational support distinguish these positions as flexible robotic procedures expand within established and emerging care pathways.